Figure 1. Discontinuation of statin therapy did not affect erythrocyte-bound apolipoprotein B (ery-apoB).

Ery-apoB was measured in subjects using statins (N = 54) at baseline and after discontinuing statin therapy for 6 weeks. Individual ery-apoB levels remained fairly stable during the 6 weeks of follow-up since ery-apoB at baseline was strongly correlated to ery-apoB after discontinuing statin therapy for 6 weeks (Spearman r: 0.828; P<0.001).